Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Antonio Addis

Showing results (1-10 of 111) with videos related to

Pageof 12
Sort By:
Recenti Progressi in Medicina|April 25, 2018
[Biosimilars: Italian Medicines Agency takes position.]Antonio Addis
Recenti Progressi in Medicina|April 23, 2020
[CoViD-19: we knew everything but we didn't understand anything.]Antonio Addis
Recenti Progressi in Medicina|February 24, 2021
[From drug evaluation to that of a path: the challenges for regulatory authorities.]Antonio Addis
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology|December 24, 2004
[Prevention of cardiovascular diseases: role of the regulatory bodies]Antonio Addis
Epidemiologia E Prevenzione|December 16, 2025
[Talking about data, what is real?]Antonio Addis
Recenti Progressi in Medicina|November 16, 2021
[Early but not too much.]Antonio Addis
Epidemiologia E Prevenzione|November 10, 2017
[Big data versus randomized clinical trials? Nobody benefits from the contrast]Antonio Addis
Recenti Progressi in Medicina|June 27, 2013
[From the "note limitative" to the "registri AIFA"]Antonio Addis, Nello Martini
Recenti Progressi in Medicina|February 3, 2017
[Equivalence, equity and evidence for the use of biosimilar drugs.]Francesco Trotta, Antonio Addis
Pharmacoepidemiology and Drug Safety|January 7, 2003
New approaches to analysing prescription data and to transfer pharmacoepidemiological and evidence-based reports to prescribersAntonio Addis, Nicola Magrini
Pageof 12

Showing results (1-10 of 111) with videos related to

Sort By:
Pageof 12
Recenti Progressi in Medicina|April 25, 2018
[Biosimilars: Italian Medicines Agency takes position.]Antonio Addis
Recenti Progressi in Medicina|April 23, 2020
[CoViD-19: we knew everything but we didn't understand anything.]Antonio Addis
Recenti Progressi in Medicina|February 24, 2021
[From drug evaluation to that of a path: the challenges for regulatory authorities.]Antonio Addis
Italian Heart Journal : Official Journal of the Italian Federation of Cardiology|December 24, 2004
[Prevention of cardiovascular diseases: role of the regulatory bodies]Antonio Addis
Epidemiologia E Prevenzione|December 16, 2025
[Talking about data, what is real?]Antonio Addis
Recenti Progressi in Medicina|November 16, 2021
[Early but not too much.]Antonio Addis
Epidemiologia E Prevenzione|November 10, 2017
[Big data versus randomized clinical trials? Nobody benefits from the contrast]Antonio Addis
Recenti Progressi in Medicina|June 27, 2013
[From the "note limitative" to the "registri AIFA"]Antonio Addis, Nello Martini
Recenti Progressi in Medicina|February 3, 2017
[Equivalence, equity and evidence for the use of biosimilar drugs.]Francesco Trotta, Antonio Addis
Pharmacoepidemiology and Drug Safety|January 7, 2003
New approaches to analysing prescription data and to transfer pharmacoepidemiological and evidence-based reports to prescribersAntonio Addis, Nicola Magrini
Pageof 12